Lumateperone Shows Benefit for Bipolar Mania

A second pivotal phase III trial found the once-daily antipsychotic improved symptoms of acute bipolar I mania versus placebo.

Updated on Nov. 6, 2026 in Mental Health

Lumateperone Shows Benefit for Bipolar Mania

Live Poll

Would you trust a newly approved psychiatric medication for a serious mood disorder?

A phase III trial showed lumateperone improved symptoms of acute bipolar I mania compared with placebo, with significant differences first observed by day 3. Lumateperone is not currently approved for treating manic episodes associated with bipolar I disorder.

Why it matters

The results add to the evidence base for lumateperone, which is already approved for bipolar depression, schizophrenia, and adjunctive treatment of major depressive disorder. Mania treatment would expand its use if regulators later approve the indication.

The trial enrolled 351 patients randomized 1:1 to lumateperone 42 mg or placebo for three weeks, with a 3.7-point greater reduction in Young Mania Rating Scale scores than placebo by day 22. Long-term outcomes beyond the three-week double-blind period were not reported in the extraction.

The players

Lumateperone

A once-daily oral antipsychotic already approved for bipolar depression, schizophrenia, and adjunctive treatment of major depressive disorder.

John McIntyre

A researcher affiliated with the University of Toronto who is the lead author of the trial report.

Michael Thase

A researcher at the University of Pennsylvania in Philadelphia who commented on the findings.

The details

Patients were randomized to three weeks of lumateperone 42 mg or placebo, beginning in an inpatient setting, with discharge to outpatient care eligible after week two. Treatment-emergent adverse event and discontinuation rates were similar to placebo, and the trial was presented at the NEI Fall Congress in Colorado Springs, Colorado.

Day 3: Significant symptom differences versus placebo first observed.
Week 2: Patients became eligible for discharge to outpatient care.
Day 22: Primary YMRS superiority over placebo measured.
November 6, 2026: Trial presented at the NEI Fall Congress.

Health Landscape

This result is the second pivotal phase III study of lumateperone for acute bipolar mania, extending an earlier trial with a replicated efficacy finding. Mania treatment options remain a separate indication from the bipolar depression approval the drug already holds.

Lumateperone is not yet approved for manic episodes, so patients with bipolar I mania cannot access it for that use on the basis of this trial alone. Adverse event rates were similar to placebo in the trial, though the stub does not describe longer-term safety.

The takeaway

Agreement across two pivotal trials strengthens the evidence that lumateperone can reduce acute manic symptoms in bipolar I disorder. Any clinical use for mania would depend on future regulatory review.